LIBTAYO (cemiplimab) - Non Small Cell Lung Cancer (NSCLC)

Reason for request

Clinical Benefit

Insufficient

The Committee deems that the clinical benefit of LIBTAYO (cemiplimab) in association with a platinum salt-based chemotherapy regimen, is insufficient in the MA indication to justify public funding.

Clinical Added Value

Not applicable